GSK3B and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, the Pim-1 kinase inhibitor SMI-4a was subsequently found to exert antitumor effects in both imatinib-sensitive and -resistant CML cells by increasing GSK-3β activity (56).